Fall Clinical Dermatology Conference

During an interview with Dermatology Times, Chovatiya outlined his Fall Clinical 2024 presentations on chronic hand eczema and early career controversies.

Aaron Farberg, MD, explores advancements in melanoma and cSCC prognostic tools, the role of gene expression profiling in inflammatory diseases, and initiatives aimed at supporting early-career dermatologists at Fall Clinical 2024.

The phase 3b study shows Ebglyss reduced eczema severity and itch in challenging areas, with 60% of prior dupilumab patients meeting key improvement by week 24.

Joel Gelfand, MD, discusses insights on complex psoriasis cases, comorbidity management, and the evolving role of phototherapy at Fall Clinical 2024.

Adbry achieved EASI-75 in 92.9% and IGA 0/1 in 66.7% of AD patients, with a strong safety profile.

Sun Pharma presented long-term data on Leqselvi 8 mg tablets, showing significant scalp hair regrowth in severe alopecia areata patients.

Catch up on coverage from the second day of the 2024 Fall Clinical Dermatology Conference in Las Vegas, Nevada.

Shawn Kwatra, MD, reviews key highlights of his sessions at Fall Clinical 2024 on the latest updates in itch conditions.

Shahriari highlighted advanced dermatology treatments, clinical trial inclusivity, and key care strategies for complex skin conditions at Fall Clinical 2024.

Del Rosso reviews available and upcoming monoclonal antibodies, including nemolizumab, lebrikizumab, bimekizumab, and more.

Phase 3b study showed promise in clearing moderate PsO in sensitive areas for patients unresponsive to topical treatments.

Christopher Bunick, MD, PhD, presented the latest period 2 data at Fall Clinical 2024.

Catch up on coverage from the first day of the 2024 Fall Clinical Dermatology Conference in Las Vegas, Nevada.

Clinicians presented a panel-style session at Fall Clinical, touching on the drawbacks of topical steroid use and alternatives in AD patients.

Del Rosso reviews numerous new and upcoming topical therapeutics and indications including ruxolitinib, tapinarof, and more.

Among the many sessions to be held at the Fall Clinical Dermatology Conference in Las Vegas, Nevada, several Dermatology Times Editorial Advisory Board members are preparing to share their knowledge and insights.

The conference will feature presentations on a number of disease states, therapeutic options, and new clinical data.

Share with us the topics you want to learn more about at Fall Clinical.

The conference aimed at providing dermatology clinicians with the latest in the specialty begins today in Las Vegas, Nevada.

We want to know: Will you be attending the conference in Las Vegas later this week?

Aesthetic procedures for patients with skin of color necessitate a nuanced approach that prioritizes patient safety and optimal outcomes.

If you weren’t able to attend the 2023 Fall Clinical Dermatology Conference or want to review our latest coverage and interviews, our full recap has you covered.

Catch up on coverage from the final day of the 2023 Fall Clinical Dermatology Conference.

This study aimed to evaluate the association between the disease burden of psoriasis and the switching of systemic biologic therapies in patients with both psoriasis and psoriatic arthritis.

There is a lot of conversation drumming around the boxed warnings for newer JAK inhibitors, and fact versus fiction was discussed at Fall Clinical.

Susan Taylor, MD, walked Fall Clinical attendees through an in-depth hyperpigmentation session that included melasma and its mimickers.

Kirby presented at both Fall Clinical and the Inflammatory Disease Summit in Las Vegas.

Sandra Lee, MD, and other top acne experts took the stage to debate cases and treatments.

Primary and secondary melanoma prevention factors are necessary to reduce patients’ melanoma risk.

The latest CDC data shows an uptick in syphilis, which can lead to a rare form of alopecia or a presentation of psoriasis.